Aktis raises $318M in 2026's first biotech IPO [Yahoo! Finance]
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: Yahoo! Finance
Radiopharmaceutical drug developer Aktis Oncology on Thursday said it raised $318 million from an initial public offering, the first for a biotechnology company in 2026. Aktis priced 17.65 million shares at $18 each, more than what it planned to sell, according to an updated securities filing earlier this week. It upsized the round after Eli Lilly, which previously partnered with the cancer drugmaker, stepped in to purchase $100 million, or a third of the shares. Aktis will begin trading Friday on the Nasdaq under the ticker symbol “ AKTS .” The company, which is based in Boston, is developing a twist on specialized cancer drugs that it says can hit tumor targets “outside the scope” of other radiopharmaceuticals. AKY-1189, its most advanced prospect, is a “miniprotein radioconjugate” targeting Nectin-4, the same protein that Pfizer's bladder cancer drug Padcev binds to. Aktis is studying what other cancers it could be used in, with Phase 1 study results expected in the first qu
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare ConferenceGlobeNewswire
- Kyverna Therapeutics (NASDAQ:KYTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KYTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KYTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
KYTX
Earnings
- 11/12/25 - Beat
KYTX
Sec Filings
- 1/14/26 - Form 4
- 1/12/26 - Form 8-K
- 12/22/25 - Form 4
- KYTX's page on the SEC website